Literature DB >> 8821039

Nigral and extranigral pathology in Parkinson's disease.

H Braak1, E Braak, D Yilmazer, C Schultz, R A de Vos, E N Jansen.   

Abstract

This article reviews data on the internal organization, neuronal types, and interconnections of limbic and motor components of the human brain, and the specific lesions which a few of them undergo during the course of Parkinson's disease (neuronal loss associated with the development of Lewy bodies and Lewy neurites). The severe involvement of nigral neuromelanin-laden projection cells has received particular attention during the past decades. This lesion interferes with normal function of the striatum and probably contributes to many of the motor dysfunctions characteristically occurring in Parkinson's disease. The similarly severe involvement of several areas and nuclei outside of the substantia nigra has often escaped notice. However, the pathology of Parkinson's disease cannot be completely described unless changes in these extranigral areas are taken into account. Interpretation of the characteristic lesional pattern is facilitated by combining schemata of both the limbic and motor systems. This approach reveals a key role by the amygdala and related structures in extranigral pathology. Severe lesions occur in the central amygdaloid nucleus, in nuclei projecting to the cerebral cortex in a non-specific manner, and in nuclei regulating endocrine and autonomic functions. It is suggested that extranigral lesions contribute to the development of behavioral changes and autonomic dysfunction.

Entities:  

Mesh:

Year:  1995        PMID: 8821039

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  46 in total

1.  Apathy in Parkinson's disease.

Authors:  G C Pluck; R G Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Effects of cortical and striatal dopamine D1 receptor blockade on cued versus noncued behavioral responses.

Authors:  Won Yung Choi; Cecile Morvan Campbell; Peter D Balsam; Jon C Horvitz
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

Review 3.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 4.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

5.  Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

Review 6.  [Postmortal diagnosis of Parkinson's disease].

Authors:  D Sandmann-Keil; H Braak
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

Review 7.  Accumulation of nuclear DNA damage or neuron loss: molecular basis for a new approach to understanding selective neuronal vulnerability in neurodegenerative diseases.

Authors:  Ivona Brasnjevic; Patrick R Hof; Harry W M Steinbusch; Christoph Schmitz
Journal:  DNA Repair (Amst)       Date:  2008-05-23

8.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 9.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.